TickerFacts.

Milestone Pharmaceuticals Inc. (MIST): Long-Term Debt

Annual figures by period end, from SEC filings.

$57.19M
As of 2025-12-31
$59.21M
As of 2026-06-30
2019-12-31: $02023-12-31: $49.77M2024-12-31: $53.35M2025-12-31: $57.19M$57.19M
2019-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$57.19M+7.2%2026-03-20, Balance as of period end
2024-12-31$53.35M+7.2%2026-03-20, Balance as of period end
2023-12-31$49.77Mn/a2025-03-13, Balance as of period end
No annual figure between 2019-12-31 and 2023-12-31.
2019-12-31$0n/a2020-10-23, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Milestone Pharmaceuticals Inc. (MIST)2025-12-31$57.19M+7.2%
Arbutus Biopharma Corp (ABUS)2025-12-31$0n/a
Journey Medical Corp (DERM)2025-12-31$25.28M+1.6%
Eton Pharmaceuticals, Inc. (ETON)2024-12-31$29.81Mn/a
Scienture Holdings, Inc. (SCNX)2024-12-31$2.90Mn/a
Precigen, Inc. (PGEN)2025-12-31$93.17Mn/a
Northwest Biotherapeutics Inc (NWBO)2025-12-31$60.04M-4.2%
Aquestive Therapeutics, Inc. (AQST)2025-12-31$45.00M0.0%
Aldeyra Therapeutics, Inc. (ALDX)2025-12-31$15.30M0.0%

Compare MIST, ABUS, DERM, ETON side by side · Screen every company in Pharmaceutical Preparations ↗